Benzinga

Benzinga

Benzinga

miércoles, agosto 19

Sutro Biopharma Inc

STRONASDAQ
Trade with Public
Trade with Public
$22.04
al cierre: Aug 19, 5:00 PM EST
$22.00
-0.04-0.18%
After hour: 9:02 AM EST
Ganancias: Los beneficios de Q2 2026 se publicaron el mié ago 12th, antes de la apertura del mercado
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Sutro Biopharma Financials

Sutro Biopharma (STRO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

Why is Sutro Biopharma Stock Falling On Wednesday?

Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dose and the next update planned for 2027.
Vandana Singh

PRO
Sutro Biopharma Q2 EPS $(2.33) Misses $(2.19) Estimate, Sales $9.839M Miss $13.048M Estimate

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.33) per share which missed the analyst consensus estimate of $(2.19) by 6.39 percent. This is a 66.43 percent decrease over losses of $(1.40) per share from
Benzinga Newsdesk

PRO
Sutro Biopharma Q1 EPS $(2.94) Beats $(3.77) Estimate, Sales $14.523M Beat $8.079M Estimate

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.94) per share which beat the analyst consensus estimate of $(3.77) by 22.02 percent. This is a 67.69 percent increase over losses of $(9.10) per share from
Benzinga Newsdesk

PRO
Sutro Biopharma Q4 EPS $(5.29) Misses $(4.35) Estimate, Sales $11.647M Beat $8.341M Estimate

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(5.29) per share which missed the analyst consensus estimate of $(4.35) by 21.58 percent. This is a 40.56 percent increase over losses of $(8.90) per share from
Benzinga Newsdesk

PRO
Sutro Biopharma Q3 EPS $(0.67) Misses $(0.41) Estimate, Sales $9.693M Beat $9.132M Estimate

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.41) by 65.02 percent. This is a 13.56 percent decrease over losses of $(0.59) per share from
Benzinga Newsdesk

PRO
Sutro Biopharma To Continue To Reorganize Restructuring And Related Costs For Deprioritzation Of Luvelta Program; Expected To Recognize Portion In 2025

Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved